OnCore Login

News & Developments

Virtual Grand Rounds: A Silver Lining for Big Ten Collaboration

December 23, 2020:

In a recent holiday post on his blog Holden the Line on Cancer, George Weiner, MD, director of the University of Iowa Holden Comprehensive Cancer Center, reflects on the resilience, creativity, and enduring commitment that has kept research collaborations strong throughout this tumultuous year. As one example, Dr. Weiner writes about the newly introduced Big Ten CRC Grand Rounds:

“One of the primary goals of an academic cancer center is to train the next generation of cancer clinicians and researchers. Our approach to such education has been changed, but not halted, by the pandemic. I continue to have weekly meetings with my research group by Zoom. In fact, my clinical research colleagues are more likely to participate virtually in these meetings now since they can do so from their offices or clinic and don’t have to walk to the other side of the medical center. I continue to meet weekly with graduate students in my laboratory. This has worked fairly well. It has become a standing joke that just about every Zoom meeting starts with a graduate student asking me to ‘enable screen sharing’ so we can review their data and plans together. Grand rounds and other conferences including tumor board discussions are held virtually as well. Not ideal but it works. As we all have gotten used to virtual conferences, we realized such meetings don’t need to be limited to a single institution. Holden suggested and organized the first Big Ten Cancer Research Consortium Grand Rounds that is a virtual meeting now held monthly. Typical attendance over the past few months has included around 100 researchers from multiple institutions. New collaborations between cancer centers in the Big Ten are starting to emerge from these discussions. Hopefully Big Ten Cancer Research Consortium Grand Rounds will continue post-pandemic and be seen as a silver lining that emerged from this very difficult time.” Read More

Hrinczenko: A Bright Future for Cancer Research at MSU

December 15, 2020: After more than 20 years in cancer research, Borys Hrinczenko, MD, PhD, sees a bright future. As a lung cancer specialist at the Michigan State University Breslin Cancer Center, he has led numerous clinical trials and helped pioneer new therapies, including checkpoint inhibitors, harnessing the body’s immune system against lung cancer. Twenty years ago, he could offer his lung cancer patients few viable treatments. More recently, “I’ve had patients who have done quite well” on checkpoint inhibitors, Hrinczenko said. That includes a small group of long-term survivors with advanced lung cancer. He expects more breakthroughs as the Breslin Cancer Center looks forward to moving into a new... Read More

Across the Consortium: November 2020

November 16, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights several new research studies, study publications, grant awards, professional appointments, and an endowment established to support cancer research. Learn what’s happening across the Big Ten CRC. Read More

Member Feature: University of Michigan Rogel Cancer Center

November 3, 2020: This month, the Big Ten Cancer Research Consortium highlights the University of Michigan Rogel Cancer Center as our featured member. Rogel Cancer Center member Ajjai Alva, MBBS, is an associate professor of hematology/oncology and member of the Big Ten CRC's Genitourinary Clinical Trial Working Group. He has participated in four Big Ten CRC trials with a few more in the pipeline. Dr. Alva shares why he is glad to be part of the Big Ten Cancer Research Consortium. "Cancer Research is evolving rapidly with major new advances and that's... Read More

Across the Consortium: October 2020

October 23, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a variety of activities and accomplishments across Big Ten universities. Highlights include new leadership announcements, grant awards, study publications, and novel treatments to continue the fight against cancer. Read More

Teamwork, technology advance cancer care

October 1, 2020: Excerpt reposted with permission from the Erie Times-News. The Big Ten is best known for football. But in 2013, member universities teamed to collaborate rather than compete, in cancer research. The Big Ten Cancer Research Consortium, based at the Hoosier Cancer Research Network in Indianapolis, Ind., helps researchers at 15 universities work together to fight cancer. The consortium includes the Penn State Cancer Institute, Rutgers University Cancer Institute of New Jersey, and the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. “The idea was to get all those football colleges and cancer institutes together to build a forum so that people from member institutions can conduct collaborative research and clinical trials,” said Monika Joshi, MD, who represents the... Read More

Big Ten study tests pembrolizumab and goserelin in advanced AR+ salivary gland cancer

October 9, 2020: A Big Ten Cancer Research Consortium phase II study for adult patients with advanced salivary gland carcinoma that is androgen receptor positive (AR+), will test the combined therapy of the PD-1 inhibitor pembrolizumab and the androgen deprivation therapy goserelin. This multi-site study is now open to accrual at the University of Illinois Cancer Center (University of Illinois at Chicago); Holden Comprehensive Cancer Center, University of Iowa; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; Read More

Big Ten CRC investigators present kidney cancer study during ESMO Virtual Congress

October 9, 2020: Big Ten Cancer Research Consortium investigators recently presented an E-Poster on the BTCRC-GU16-043 study during the ESMO 2020 Virtual Congress. The clinical trial is investigating whether adding guadecitabine, a drug that targets DNA methylation, might increase the proportion of patients with advanced clear cell renal cell carcinoma (ccRCC) who respond to treatment with durvalumab, a checkpoint-inhibitor drug that targets the PD-1/PD-L1 pathway. “In the past decade, checkpoint inhibitors have been a valuable addition to the therapeutic armamentarium of kidney cancer. However, not all patients benefit from this therapy, and there is an unmet need to further improve the clinical outcomes with novel combination... Read More

Integrative Oncology Scholars Program accepting applications for 2021-2022 cohort

October 1, 2020: Applications are now open for a nationwide integrative oncology training program. The Integrative Oncology Scholars Program at the University of Michigan is funded by a National Cancer Institute R25 grant. It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Read More

Phase Ib study tests gemtuzumab ozogamicin with venetoclax in relapsed/refractory acute myeloid leukemia

September 29, 2020: A phase Ib Big Ten Cancer Research Consortium multi-center study is testing the safety and efficacy of the monoclonal antibody gemtuzumab ozogamicin when combined with the BCL-2 inhibitor venetoclax in adults with relapsed or refractory acute myeloid leukemia. The study is open to accrual at the University of Illinois Cancer Center in Chicago, Ill.; the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, Ind.; the University of Michigan Rogel Cancer Center in Ann Arbor, Mich.; and the Read More

University of Illinois

University of Illinois

Indiana University

Indiana University

University of Iowa

University of Iowa

University of Maryland

University of Maryland

University of Michigan

University of Michigan

Michigan State

Michigan State

University of Minnesota

University of Minnesota

University of Nebraska

University of Nebraska

Northwestern University

Northwestern University

Penn State University

Penn State University

Purdue University

Purdue University

Rutgers State University

Rutgers State University

University of Wisconsin

University of Wisconsin

University of Illinois at Chicago

University of Illinois at Chicago

© 2024 All rights reserved.

Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278

email: info@bigtencrc.org    phone: 317–921–2050